These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

285 related items for PubMed ID: 20546257

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Peroxisome proliferator-activated receptor gamma agonism modifies the effects of growth hormone on lipolysis and insulin sensitivity.
    Krag MB, Nielsen S, Guo Z, Pedersen SB, Schmitz O, Christiansen JS, Jørgensen JO.
    Clin Endocrinol (Oxf); 2008 Sep; 69(3):452-61. PubMed ID: 18331610
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Improved insulin sensitivity after treatment with PPARγ and PPARα ligands is mediated by genetically modulated transcripts.
    Rasouli N, Kern PA, Elbein SC, Sharma NK, Das SK.
    Pharmacogenet Genomics; 2012 Jul; 22(7):484-97. PubMed ID: 22437669
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Pioglitazone reduces islet triglyceride content and restores impaired glucose-stimulated insulin secretion in heterozygous peroxisome proliferator-activated receptor-gamma-deficient mice on a high-fat diet.
    Matsui J, Terauchi Y, Kubota N, Takamoto I, Eto K, Yamashita T, Komeda K, Yamauchi T, Kamon J, Kita S, Noda M, Kadowaki T.
    Diabetes; 2004 Nov; 53(11):2844-54. PubMed ID: 15504964
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Effect of tesaglitazar, a dual PPAR alpha/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial.
    Goldstein BJ, Rosenstock J, Anzalone D, Tou C, Ohman KP.
    Curr Med Res Opin; 2006 Dec; 22(12):2575-90. PubMed ID: 17166340
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Synthesis and evaluation of new 1,2,4-oxadiazole based trans- acrylic acid derivatives as potential PPAR-alpha/gamma dual agonist.
    Kaur P, Bhat ZR, Bhat S, Kumar R, Kumar R, Tikoo K, Gupta J, Khurana N, Kaur J, Khatik GL.
    Bioorg Chem; 2020 Jul; 100():103867. PubMed ID: 32353564
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.